NCT02194530

Reduction of Peanut Reactivity and Immune Modulation With Anti-IgE Therapy

Completed Last updated 6 December 2023

What this trial tests

trial in Peanut Allergy in 11 participants. Completed in 19 July 2016.

Timeline

30 March 2015

Primary endpoint
19 July 2016

19 July 2016

Quick facts

Lead sponsor	Weill Medical College of Cornell University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	11
Start date	30 March 2015
Primary completion	19 July 2016
Estimated completion	19 July 2016
Sites	1 location across United States

Conditions studied

• Peanut Allergy — all drugs for Peanut Allergy →

Sponsor

Weill Medical College of Cornell University

Who can join

Adults 18 to 65, any sex, with Peanut Allergy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot study is will examine the pathways involved in allergic response, primarily in food allergy; specifically peanut allergy. We will also study non-allergic donors as well as patients with atopic disorders, primarily as control subjects. We believe that this study will lead to discovery of significant pathways involved in the allergic pathway that can be explored in more detail during follow-up studies in order to address mechanistic questions that cannot be answered in a pilot trial. We believe that such a pilot study represents the ideal approach to identify effective therapeutic interventions and to simultaneously better understand the underlying mechanistic properties involved in the allergy cascade. We think that this study forms the basis for a novel avenue of research into the pathogenesis of allergic pathways, a disease that is still associated with significant morbidity and mortality.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.